Presentation Title

Functional NK Cell-Mediated ADCC Killing Assay and Protocol in B-Cell Lymphoma

Presenter Information

arriana blackmonFollow

Advisor Information

Paul Denton

Location

MBSC Ballroom - Poster #806 - U

Presentation Type

Poster

Start Date

4-3-2022 10:45 AM

End Date

4-3-2022 12:00 PM

Abstract

In the Denton Immunobiology Lab, we use human natural killer (NK) cells to kill cancer cells. Specifically, my project is using NK cells to kill lymphoma cells in an indirect manner termed ADCC (antibody dependent cellular cytotoxicity). To measure how much killing occurs in our experiments we utilize a flow cytometry-based assay. I participated in the establishment of the baseline parameters of our flow cytometry-based “killing assay” protocol and will discuss some of these in my poster. For my FUSE project, I proposed to evaluate the impact of anti-PD1 immunotherapy on NK cell killing capacity. My lab colleagues and I preformed many experiments jointly because of the limited number of human cells available and the overlap in control conditions that we tested. In my poster, I will present our data-to-date regarding the impact on NK cell killing of lymphoma cell plus/minus anti-PD1 immunotherapy.

This document is currently not available here.

COinS
 
Mar 4th, 10:45 AM Mar 4th, 12:00 PM

Functional NK Cell-Mediated ADCC Killing Assay and Protocol in B-Cell Lymphoma

MBSC Ballroom - Poster #806 - U

In the Denton Immunobiology Lab, we use human natural killer (NK) cells to kill cancer cells. Specifically, my project is using NK cells to kill lymphoma cells in an indirect manner termed ADCC (antibody dependent cellular cytotoxicity). To measure how much killing occurs in our experiments we utilize a flow cytometry-based assay. I participated in the establishment of the baseline parameters of our flow cytometry-based “killing assay” protocol and will discuss some of these in my poster. For my FUSE project, I proposed to evaluate the impact of anti-PD1 immunotherapy on NK cell killing capacity. My lab colleagues and I preformed many experiments jointly because of the limited number of human cells available and the overlap in control conditions that we tested. In my poster, I will present our data-to-date regarding the impact on NK cell killing of lymphoma cell plus/minus anti-PD1 immunotherapy.